Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
出版年份 2021 全文链接
标题
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume 22, Issue 5, Pages 609-619
出版商
Elsevier BV
发表日期
2021-04-10
DOI
10.1016/s1470-2045(21)00056-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- NCCN Guidelines Insights: Cervical Cancer, Version 1.2020
- (2020) Nadeem R. Abu-Rustum et al. Journal of the National Comprehensive Cancer Network
- Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
- (2020) Chunyan Lan et al. JOURNAL OF CLINICAL ONCOLOGY
- Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
- (2019) Johann S de Bono et al. LANCET ONCOLOGY
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Joint ENGOT and GOG Foundation requirements for trials with industry partners
- (2019) Ignace Vergote et al. GYNECOLOGIC ONCOLOGY
- Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma
- (2019) Krishnansu S. Tewari et al. JOURNAL OF CLINICAL ONCOLOGY
- Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
- (2019) David S. Hong et al. CLINICAL CANCER RESEARCH
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
- (2017) H Miles Prince et al. LANCET
- Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review
- (2016) Stergios Boussios et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505
- (2015) Ryo Kitagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody-Drug Conjugates
- (2015) B. E. C. G. de Goeij et al. MOLECULAR CANCER THERAPEUTICS
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer
- (2014) Johanna Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Bevacizumab in Advanced Cervical Cancer
- (2014) Krishnansu S. Tewari et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
- (2013) E. C. W. Breij et al. CANCER RESEARCH
- Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor
- (2011) Emiliano Cocco et al. BMC CANCER
- Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group
- (2009) D. Lorusso et al. ANNALS OF ONCOLOGY
- Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study
- (2009) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
- (2009) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group
- (2008) David Scott Miller et al. GYNECOLOGIC ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now